Video

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Related Videos
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Shaji Kumar, MD
Shaji Kumar, MD
5 KOLs are featured in this series.
Related Content
OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.
November 25th 2024

FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Multiple myeloma Image credit: LASZLO – stock.adobe.com
November 15th 2024

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma